Insider Selling: Seer (NASDAQ:SEER) CFO Sells $14,837.27 in Stock

Seer, Inc. (NASDAQ:SEER) CFO David Horn sold 7,309 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $2.03, for a total value of $14,837.27. Following the sale, the chief financial officer directly owned 486,650 shares in the company, valued at $987,899.50. This represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Seer Trading Up 1.5%

Seer stock traded up $0.03 during mid-day trading on Wednesday, hitting $2.05. The company had a trading volume of 182,540 shares, compared to its average volume of 632,272. The company has a market capitalization of $112.71 million, a price-to-earnings ratio of -1.68 and a beta of 1.55. The company’s fifty day moving average is $1.97 and its 200-day moving average is $1.88. Seer, Inc. has a 12-month low of $1.55 and a 12-month high of $2.41.

Seer (NASDAQ:SEER) last posted its earnings results on Tuesday, August 11th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Seer had a negative net margin of 478.05% and a negative return on equity of 27.23%. The firm had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.55 million.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SEER. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research report on Friday, July 17th. Canaccord Genuity Group started coverage on Seer in a research report on Monday, May 4th. They set a “buy” rating and a $4.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $4.00.

Institutional Investors Weigh In On Seer

Several large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its position in shares of Seer by 51.6% in the first quarter. Goldman Sachs Group Inc. now owns 170,897 shares of the company’s stock valued at $289,000 after acquiring an additional 58,173 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Seer by 33.3% in the first quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock worth $430,000 after acquiring an additional 63,432 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Seer by 16.5% during the second quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock worth $1,091,000 after purchasing an additional 72,265 shares in the last quarter. XTX Topco Ltd acquired a new position in Seer in the 2nd quarter valued at $172,000. Finally, Occudo Quantitative Strategies LP acquired a new position in Seer in the 2nd quarter valued at $25,000. 75.20% of the stock is currently owned by hedge funds and other institutional investors.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.